Milliplex map for luminex xmap technology

Manufactured by Merck Group

Sourced in United States

Milliplex™ MAP for Luminex® xMAP™ technology is a multiplex assay platform that enables the simultaneous detection and quantification of multiple analytes in a single sample. The core function of this product is to provide a versatile and efficient tool for researchers to analyze complex biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Architect analyzer, by Abbott (1 mentions) Paxgene blood rna tube, by Qiagen (1 mentions) Milliplex mouse cytokine magnetic kit, by Merck Group (1 mentions)

4 protocols using milliplex map for luminex xmap technology

Biomarkers in Kidney Transplant Monitoring

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood and urine samples were obtained in pre-defined times (before and one and three months after kidney transplantation) for laboratory tests and tacrolimus monitoring. Blood samples were also obtained in PAXgene™ blood RNA tubes (Qiagen GmbH, Hilden, Germany) for RNA extraction.
Creatinine, urea, glucose, total cholesterol, HDL cholesterol and triglycerides were measured by automated methods. The eGFR was calculated using the four-variable MDRD formula (28 (link)). Three months after the transplant, plasma levels of some cytokines such as interferon-γ (IFN-γ), interleukin (IL)-2, IL-4, IL-10 and IL-17 were measured by immunoassays Milliplex™ MAP for Luminex^® xMAP™ technology (Merck Millipore, Massachusetts, USA).
Tacrolimus blood concentration was measured by an immunoassay using the Abbott Architect analyzer (Abbott Diagnostics, Illinois, USA). The tacrolimus C/D [ng/(mL·mg)] was calculated for each patient.
The biopsy-confirmed acute rejection (BCAR) was performed by the local pathologist according to the Banff 2003 classification (29 (link)). The delayed graft function (DGF) was considered to be the dialysis performed in 7 days after transplantation.

Bonezi V., Genvigir F.D., Salgado P.D., Felipe C.R., Tedesco-Silva H J.r., Medina-Pestana J.O., Cerda A., Doi S.Q., Hirata M.H, & Hirata R.D. (2020). Differential expression of genes related to calcineurin and mTOR signaling and regulatory miRNAs in peripheral blood from kidney recipients under tacrolimus-based therapy. Annals of Translational Medicine, 8(17), 1051.

+ Open protocol

+ Expand

Cytokine Immunoassay of Plasma and Dialysate

Check if the same lab product or an alternative is used in the 5 most similar protocols

The plasma and dialysate samples were analyzed at the Clinical Research Department, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden with the commercial High Sensitivity Human Cytokine Magnetic Bead Panel Immunoassay (MILLIPLEX®MAP for Luminex® xMAP® Technology, EMD Millipore, Missouri, USA). The minimum detectable concentration (MinDC) were 0.06 pg/mL for IL-1β, 0.20 pg/mL for IL-6, 0.05 pg/mL for IL-8, and 0.07 pg/mL for TNF. Samples that were regarded as “out of range” by the program were considered as 0 pg/mL.

Christidis N., Ghafouri B., Larsson A., Palstam A., Mannerkorpi K., Bileviciute-Ljungar I., Löfgren M., Bjersing J., Kosek E., Gerdle B, & Ernberg M. (2015). Comparison of the Levels of Pro-Inflammatory Cytokines Released in the Vastus Lateralis Muscle of Patients with Fibromyalgia and Healthy Controls during Contractions of the Quadriceps Muscle – A Microdialysis Study. PLoS ONE, 10(12), e0143856.

+ Open protocol

+ Expand

Plasma Biomarkers Post-Myocardial Infarction

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma was collected according to the above mentioned protocols at days 3, and 7 post-MI. Inflammatory biomarkers (IL-12, IL-1β, IL-1α, IL-6, TNF-α, MCP-1, MIP-1a and MIP-1b) were assayed using the Milliplex mouse cytokine magnetic kit (MILLIPLEX MAP for Luminex xMap Technology, Millipore, USA) according to the manufacturer’s protocol.

Al-Darraji A., Haydar D., Chelvarajan L., Tripathi H., Levitan B., Gao E., Venditto V.J., Gensel J.C., Feola D.J, & Abdel-Latif A. (2018). Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease. PLoS ONE, 13(7), e0200474.

+ Open protocol

+ Expand

Inflammatory Biomarkers Post-Myocardial Infarction

Check if the same lab product or an alternative is used in the 5 most similar protocols

At 1- and 3-days post-MI, inflammatory biomarkers (IL-1β, IL-1α, TNF-α, MIP-1α, MIP1β, MIP2, IP-10, and KC) were quantified in plasma using the Milliplex mouse cytokine magnetic kit (MILLIPLEX MAP for Luminex xMap Technology, Millipore, USA) according to the manufacturer’s protocol.

Al-Darraji A., Donahue R.R., Tripathi H., Peng H., Levitan B.M., Chelvarajan L., Haydar D., Gao E., Henson D., Gensel J.C., Feola D.J., Venditto V.J, & Abdel-Latif A. (2020). Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction. Scientific Reports, 10, 16596.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!